The incidence of hyperkalemia is low in large controlled clinical trials of angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists, whereas a higher incidence is observed in clinical practice due to the co‐administration of these potassium‐altering drugs.32, 33, 34. This evidence concerns the gene ACE and Hyperkalemia.